5 Health Care Stocks Pushing The Sector Higher

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 165 points (1.1%) at 15,235 as of Monday, June 17, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 2,604 issues advancing vs. 474 declining with 57 unchanged.

The Health Care sector currently sits up 0.4% versus the S&P 500, which is up 1.0%. Top gainers within the sector include Illumina ( ILMN), up 4.1%, Zimmer Holdings ( ZMH), up 3.0%, Amgen ( AMGN), up 2.4%, Becton Dickinson ( BDX), up 2.0% and Stryker Corporation ( SYK), up 1.4%. On the negative front, top decliners within the sector include Vertex Pharmaceuticals ( VRTX), down 2.30, Biogen Idec ( BIIB), down 0.95, Celgene Corporation ( CELG), down 0.75, Gilead ( GILD), down 0.82 and Merck ( MRK), down 0.54.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector higher today:

5. Sanofi ( SNY) is one of the companies pushing the Health Care sector higher today. As of noon trading, Sanofi is up $1.30 (2.42) to $55.04 on average volume Thus far, 866,650 shares of Sanofi exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $54.96-$55.47 after having opened the day at $55.19 as compared to the previous trading day's close of $53.74.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $144.8 billion and is part of the drugs industry. The company has a P/E ratio of 29.0, above the S&P 500 P/E ratio of 17.7. Shares are up 13.4% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Sanofi a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Sanofi Has Good Potential Upside

European Pharma Companies Slip on MS Pricing Probe